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Role of endothelin and prostaglandins in radiocontrast-mduced renal
artery constriction. Infusion of radiocontrast agents in vivo results in
renal artery constriction and subsequent renal hypoperfusion. To
examine the role of endothelin and of prostaglandins in radiocontrast-
mediated renal vasoconstriction, rats were treated with an endothelin
receptor antagonist, CP170687, and with indomethacin. The dose of
CP170687 utilized was sufficient to reverse endothelin1-mediated con-
striction of isolated aortic rings and of renal blood flow in intact rats. In
normal rats there was a transient drop in renal blood flow to 80% of
baseline following sodium iothalamate injection, an effect which was
not prevented by CP170687. In rats first given indomethacin, the drop in
renal blood flow was more pronounced (to 63% of baseline) and was
sustained. In this instance, CP170687 fully reversed the sustained
decrease of renal perfusion. CP170687 also diminished the rise in
systemic blood pressure seen following iothalamate injection. In the
absence of indomethacin, iothalamate increased urinary prostaglandin
E2 to a maximum of sevenfold above baseline values. In summary,
injection of radiocontrast results in an immediate decrease in renal
blood flow that is counteracted by an increase in renal prostaglandin
formation. When prostaglandin synthesis is inhibited, prolonged endo-
thelin-mediated renal vasoconstriction is observed that is reversed by
an endothelin receptor antagonist.
Renal vasoconstriction with resultant tissue hypoxia, espe-
cially of the renal medulla, has been thought to play a role in the
genesis of radiocontrast nephropathy [1—3]. Potential mediators
of the vasoconstrictive response to radiocontrast agents (renin,
angiotensin II, norepinephrine) have been previously investi-
gated without finding a clear causative role for any of these
hormones [4—61. The recent finding that several iodinated ra-
diocontrast agents induce an increase in circulating endothelin
levels in rats [7] and dogs [8] suggests the hypothesis that this
class of vasoconstrictors may be involved in the renal response
to radiocontrast infusion. Heyman and coworkers showed that
15 minutes after the injection of sodium iothalamate into normal
rats, immunoreactive endothelin (El) levels increase from a
baseline of 17.3 fmol/ml to 36.2 fmol/ml [7], a finding which was
later confirmed in a rat model of radiocontrast nephropathy [9].
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The physiological significance of the rise in endothelin, how-
ever, remained uncertain.
The vasoconstrictive effects of radiocontrast administration
are likely to invoke the release of endogenous counteractive
renal vasodilators including prostaglandins. In support of this
hypothesis are previous studies showing that inhibition of
prostaglandin synthesis with indomethacin is necessary for the
production of experimental radiocontrast nephropathy in rats
and rabbits [1, 10, 11], as well as studies showing stimulation of
prostaglandin E2 (POE2) and prostacyclin production by endo-
thelin [12, 13].
The present experiments were designed to test these hypoth-
eses. Injections of sodium iothalamate increased urinary POE2
excretion and produced transient renal vasoconstnction in
normal rats. More severe and prolonged reductions in renal
blood flow were produced by radiocontrast in animals pre-
treated with indomethacin. Administration of a recently identi-
fied cyclic peptide endothelin receptor antagonist (CP170687)
did not prevent the transient renal vasoconstriction seen in
normal rats, but reversed the prolonged renal vasoconstriction
and hypertension observed when prostaglandin synthesis was
inhibited. The results support a role for endothelin in promoting
radiocontrast-induced renal vasoconstriction and for pros-
taglandins in opposing that effect.
Methods
Endothelin receptor antagonist CP170687
The tripeptide antagonist CP170687 shown in Figure 1 was
synthesized using standard solution phase procedures similar to
methods described in detail elsewhere [14].
Effects of CPJ 70687 in isolated rat aorta
Male Sprague-Dawley rats (300 to 350 g) were given an
overdose of pentobarbital intraperitoneally. The thoracic aortas
were quickly removed and placed in oxygenated (95% 02/5%
C02) Krebs solution of the following composition (mM): NaCI
130, NaHCO3 25, KCI 5, NaH2PO4 1.2, MgSO4 1.2, CaCl2 2.5,
d-glucose 11.4 (pH 7.4). Adherent fat and connective tissue
were removed and the aortas were cut into 3-mm ring segments.
Endothelium was removed from the rings by inserting a
rolled-up filter paper into the lumen of the vessel several times.
The rings were then mounted in a muscle bath, between a
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moveable and a fixed stainless steel wire, with the moveable
end attached to an F1'03 force displacement transducer (Grass
Instruments, Quincy, Massachusetts, USA) coupled to a Model
7D Grass Polygraph for recording isometric tension responses.
The muscle bath was filled with 10 ml of Krebs solution
continuously bubbled with 95% 02/5% CO2. The preparations
were equilibrated for one hour before 500 mg of passive tension
was placed on the rings, which were then contracted twice by
the addition of 50 mri KCI to the muscle bath. Cumulative
concentration-contraction curves for ET1 were then obtained in
the presence or absence of CP170687 from adjacent segments of
the same aorta. Vessels were equilibrated with CP170687 for 10
minutes prior to beginning the ET1 concentration-contraction
curve. EC50 values were calculated from these curves and pA2
values were determined from Schild analysis using the method
of least squares [15].
The specificity of CP170687 as an antagonist in rat aorta was
evaluated by determining the effect of 100 sM CP170687 on the
contractile response to KCI (50 mM) or phenylephrine. In these
experiments, adjacent rings were exposed to either the vehicle
or CP170687 for 10 minutes, then contracted with either 50 mri
KCI or increasing concentrations of phenylephrine (to a maxi-
mum of 10 LM).
Phenylephrine (L-phenylephrine HC1) was obtained from
Sigma Chemical Co. (St. Louis, Missouri, USA) and dissolved
in distilled H20. CP170687 was synthesized in the Department
of Chemical Sciences (Monsanto Co.) and dissolved in distilled
H20. Endothelin1 (ET1-human) was obtained from Peptides
International (Louisville, Kentucky, USA). A stock solution of
ET1 in distilled H20 was made at a concentration of 100 jiM.
Dilutions from this stock were made using 0.05% bovine serum
albumin in 0.9% NaC1.
Endothelin-1 infusion
Male Sprague-Dawley rats (350 to 450 g wt) were anesthe-
tized with mactin (BYK Gulden, Konstanz, Germany, 100
mg/kg body wt) and the left flank exposed. A pulsed Doppler
probe (Valpey-Fisher, Hopkinton, Massachusetts, USA) was
positioned on the left renal artery and the signal continuously
recorded. Simultaneous recording of systemic blood pressure
was performed through a femoral artery catheter coupled to a
pressure transducer. A continuous infusion of ET1 (Sigma
Chemical Company) in graded amounts from 2.17 to 21.7
pmollmin was given through a PE-lO (Clay-Adams, Parsippany,
New Jersey, USA) femoral vein catheter.
Radiocontrast infusion experiments
Rats were anesthetized with mactin and renal blood flow and
systemic blood pressure were continuously recorded as above.
Sodium iothalamate, 80% (Angio Conray; Mallinckrodt, Inc.,
St. Louis, Missouri, USA) 6 mI/kg was administered at time
zero at 1.1 mI/mm through a PESO catheter placed in the femoral
artery. In receptor antagonist experiments, CP170687 was
dissolved in normal saline and injected at a dose of 6.0 mg/lOO
g body wt (0.3 mI/100 g body wt injected i.v. over 1 to 2 mm)
five minutes before the sodium iothalamate infusion. In exper-
iments involving pretreatment with a prostaglandin synthesis
inhibitor, indomethacin (Sigma Chemical Co.) 10 mg/kg dis-
solved in phosphate buffer (pH 8) was injected into the femoral
vein 60 minutes before the infusion of radiocontrast. Rats were
maintained at 37°C in a constant temperature chamber and a
continuous 0.037 mI/mm infusion of normal saline was admin-
istered to prevent volume depletion. Control experiments were
performed with infusion of 6 mI/kg of 1.32 M NaCl (equal
tonicity to the sodium iothalamate).
Model of contrast nephropathy
The model utilized has been previously described in detail
[1]. Briefly, male Sprague-Dawley rats (350 to 480 g wt)
underwent uninephrectomy, followed three weeks later by salt
depletion with three daily intraperitoneal injections of fu-
rosemide (2 mg/kg) and a low-salt diet (ICN Nutritional Bio-
chemicals, Cleveland, Ohio, USA) for a week. The rats were
anesthetized with mactin and put in a warmed 37°C chamber.
Indomethacin (10 mg/kg) was injected into the femoral vein and
60 minutes later 6 mI/kg of 80% sodium iothalamate was
administered as above.
Urinary PGE2 measurements
A PESO catheter was inserted into the dome of the bladder for
continuous urine collection. Thirty minutes prior to injection of
radiocontrast or 1.32 M NaC1 (isotonic to the sodium iothala-
mate), urine collection was initiated and continued for 60
minutes (3 20-mm collection periods) following injection of
contrast. Urine samples were frozen at —20°C until the time of
assay.
Assays were performed using a standard double antibody
radioimmunoassay with reagents obtained from New England
Nuclear (Dupont, Boston, Massachusetts, USA). Urine sam-
ples were diluted 1:20 and assayed in duplicate. The lower limit
of assay detection was 0.125 pg/assay tube; ED50 is 1.6 pg/assay
tube. Cross reactivity was 100% for PGE2, 3.7% for PGE1, and
less than 1% for PGA2, PGF,, PGF2 and thromboxane B2.
Intra-assay coefficient of variation was 4 to 6% and interassay
coefficient of variation was 10 to 12%.
Statistics
All results are expressed as mean SEM. Statistical signifi-
cance in all cases was determined using multivariant ANOVA
with repeated measures.
Resufts
Effects of CP170687 in isolated rat aorta
CP170687 was tested for antagonism of ET1 induced contrac-
tile responses in isolated rat aortic rings. The concentration-
contraction curve for ET1 was shifted to the right by CP170687
in a dose-dependent and parallel manner (Fig. 2). At all con-
centrations of the antagonist tested, the maximal response to
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Fig. 1. Structure of CPJ 70687.
H
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Fig. 2. Antagonism of El', by CP170687 in isolated aortic rings.
Symbols are: (0) ET1; (•) 3 x l0 M CPI70687 + ET1; (A) l06 M
CP170687 + ET1; (•) lO M CP170687 + ET1. Isolated rat aortic rings
were bathed in increasing concentrations of endothelin1 in the presence
and absence of CP170687 at the concentrations listed. Contractile
responses were measured and normalized to the maximal response
obtained with addition of 50 msi KCI. Results are expressed as mean
SEM (N = 3).
ET1 was obtained, indicating that CP170687 acted in a revers-
ible manner. Schild analysis of these data yielded a pA2 value of
6.37 0.09 and a slope of 1.04 0.11. Thus in this tissue
CP170687 behaved as a competitive, fully reversible antagonist
of ET1.
The specificity of CP170687 was examined by measuring the
effect of a high concentration of the compound on the contrac-
tile effects of other agonists in rat aorta. One hundred micro-
moles CP170687 did not inhibit the contractile effect of 50 mri
KC1 (102 0.6% of control response; N = 6). Likewise, 100 LM
CP170687 had no effect on the contractile response to 10 M
phenylephrine (EC5O 16.0 1.5 n vs. 14.0 1.5 m, vehicle
vs. CP170687). These data indicate that CP170687 prevents the
receptor-mediated contraction of ET1, but not the less specific
actions of KCI and phenylephrine.
Effects of endothelin receptor antagonist (CPJ 70687) on
endothelin-induced renal vasoconstriction and systemic
hypertension
To determine an effective in vivo dose of the endothelin
receptor antagonist in the rat, renal blood flow (RBF) and mean
arterial blood pressure (MAP) were monitored during a contin-
uous infusion of ET1 in the presence or absence of CP170687
(Fig. 3). The ET1 infusion was progressively increased from
2.17 to 21.7 pmol/min, producing a maximal fall in RBF to 21%
of initial levels and a maximal increase in MAP of 46 mm Hg in
the absence of CP170687.
Intravenous injection of 1.2 mg/100 g body wt CP170687 five
minutes prior to the ET1 infusion resulted in complete blockade
of the renal vasoconstrictive effect of low-dose endothelin (2.17
to 4.22 pmollmin), but did not prevent the fall in RBF at high
dose ET1 (21.7 pmol/min). Similarly, the rise in MAP produced by
the ET1 infusion was prevented only at the lower infusion rates of
ET1. A higher dose of the antagonist, 6.0 mg/100 g body wt, on the
Time, minutes
Fig. 3. Antagonism of ET, by CPI 70687 in intact rats. Effects on RBF
and MAP. Symbols are: (0) ET1; (•) El1 + CP170687 (1.2 mg/l00 g);
(•) ET1 + CP170687 (6.0 mg/lOO g). Rats were given an intravenous
infusion of ET1 while renal blood flow (RBF) (A, expressed as % of
baseline value) and mean arterial pressure (MAP) were continuously
monitored. Control rats (N = 5) are compared to rats pre-treated with
CP170687 at 1.2 (N = 4) or 6.0 (N = 5) mg/l00 g. Results are expressed
as mean SCM. *P = 0.01 vs. 1.2mg CP170687, P = 0.001 vs. control;
= 0.02vs. control; *** = 0.04 vs. 1.2mg CP170687, P <0.001 vs.
control.
other hand, significantly blunted both the fall in RBF and the rise
in MAP seen even with the highest infusion rate of El'1.
The injection into control rats of 6.0 mgJlOO g body wt
CP170687 in the absence of ET1 resulted in essentially no
change in renal blood flow, but did cause a transient (10 to 15
mm) rise in mean arterial blood pressure, with a peak increase
five minutes after injection of approximately 10 to 15 mm Hg
(data not shown). Blood pressure then returned to baseline by
15 minutes and remained stable throughout the remainder of the
60 minute time period.
Effects of endothelin receptor blockade on circulatory and
renal responses to sodium iothalamate
As reported earlier, a 6 mI/kg infusion of sodium iothalamate
into rats results in an immediate but transient drop in renal
blood flow to about 80% of basal values, with recovery over the
ensuing 30 minutes [3]. This is accompanied by a rise in
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Fig. 4. Effects of radiocontrast on RBF and MAP with (0) and without(•) CPJ70687. Rats were given 6 mI/kg sodium iothalamate without (N
= 4) or with pre-treatment with 6.0 mg/l00 g CP170687 (N = 5). RBF
(A, expressed as % of baseline value) and mean arterial pressure were
continuously monitored. Results are expressed as mean SEM.
0.001 vs. iothalamate alone.
Effect of endothelin receptor blockade on responses to
iothalamate in the presence of indomethacin
To determine the role that prostaglandins might play in
modulating renal blood flow and systemic blood pressure re-
sponses to radiocontrast administration, rats were given indo-
methacin (10 mg/kg) prior to radiocontrast infusion, and the
effects of the endothelin receptor antagonist were again exam-
ined (Fig. 5).
In rats treated with indomethacin, iothalamate produced a
Time, minutes
Fig. 5. Effects of indomethacin and CP170687 on radiocontrast-in-
duced vasoconstriction in normal rats. Rats were treated with sodium
iothalamate alone (•; 6 mI/kg, N = 4), iothalamate + indomethacin (U;
10 mg/kg 60 mm before iothalamate, N = 5), and iothalamate +
indomethacin + CP170687 (0; 6 mg/100 g 5 mm before iothalamate, N
4). Renal blood flow (A, expressed as % of baseline) and mean arterial
pressure were continuously monitored. Results expressed as mean
SEM. *p < 0.0001 vs. iothalamate, P < 0.0001 vs. iothalamate +
indomethacin + CP170687; **D = 0.0005 vs. iothalamate; <
0.0001 vs. iothalamate, P = 0.0001 vs. iothalamate + indomethacin.
two times greater decline in renal blood flow (to 63% of baseline
values vs. 80% with iothalamate alone), although the initial rise
in systemic blood pressure seen with iothalamate alone was
lessened. Furthermore, in the presence of indomethacin renal
vasoconstriction was prolonged, persisting throughout the ex-
perimental period (Fig. 5). Treatment with CP170687 five min-
utes before iothalamate infusion resulted in complete reversal
of the augmented renal artery constriction seen in rats receiving
indomethacin. As before, the sustained rise in blood pressure
that followed iothalamate injection was also reversed by the
endothein receptor antagonist.
In a related series of experiments, rats were subjected to
uninephrectomy and salt-depletion before injection of indo-
methacin and iothalamate, since these manipulations have been
shown to exaggerate renal injury produced by radiocontrast
agents [1]. The changes in renal blood flow and mean arterial
blood pressure following iothalamate injection into indometha-
cm treated, uninephrectomized, salt-depleted rats (Fig. 6) were
virtually identical to those changes seen with indomethacin
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systemic blood pressure coincident with a doubling of plasma
immunoreactive endothelin levels [9]. In the present study
these hemodynamic findings are confirmed and the effect of
administration of CP170687 (6 mg/l00 g body wt) is examined
(Fig. 4).
In the normal rat, the transient decline in renal blood flow
following the injection of 6 mI/kg sodium iothalamate was not
prevented by the addition of CP170687. However, the sustained
rise in systemic blood pressure due to sodium iothalamate was
partially reversed by the endothelin receptor antagonist. The
transient (10 to 15 mm) initial rise in MAP in the presence of the
endothelin antagonist can be ascribed to a combination of the
effects of the CP170687 itself (see above) and the injection of the
hypertonic solution.
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alone (Fig. 5). Furthermore, the addition of CP170687 again
resulted in a partial reversal of both the diminished renal blood
flow and the elevated mean arterial blood pressure, although the
latter did not reach statistical significance.
Effect of sodium iothalamate on urinary prostaglandin E2
excretion
The preceding experiments suggested that injection of so-
dium iothalamate might stimulate vasodilatory prostaglandins.
Urinary levels of prostaglandin E2 and urine flow rates were
therefore measured in experimental rats before and after injec-
tion of 6 mL/kg of sodium iothalamate (Fig. 7).
Urinary excretion of PGE2 increased abruptly after the
injection of sodium iothalamate, averaging 5 x, 2 x and 7 X its
baseline level during the three 20-minute collection periods
following its administration, in association with the expected
increase in urine flow. (A portion of the initial increase in POE2
excretion observed in the first 20-mm collection period can
presumably be attributed to the washout of urinary dead space
consequent to the diuresis.) Administration of the same volume
of hypertonic saline (1.32 M NaC1), equal in tonicity to the
sodium iothalamate solution, produced a similar solute diuresis
but a less marked rise in POE2 excretion (P < 0.05 compared
with sodium iothalamate). Indomethacin pretreatment (10
mg/kg given 60 mm before iothalamate) abolished the rise in
urinary PGE2 following radiocontrast administration.
Discussion
Endothelins are a family of at least three 21-amino acid
peptides (ET1, ET2 and ET3) secreted primarily by vascular
endothelial cells [16]. Northern blot analysis, immunoreactive
staining, and cell culture data have demonstrated that other cell
types (including renal mesangial and tubular cells) have the
capability for secreting endothelin, with tissue selectivity as to
which isoform is produced [17—19]. The principal effect of ET1,
the most studied of the three, appears to be on vascular tone,
with prolonged vasoconstriction in most vascular beds (includ-
ing renal) and vasodilatation in others [16, 20].
At least two endothelin receptors have been identified, ETa
and ETb, with ETa receptors having selective affinity for ET1
and ET2 and ETb receptors having similar affinities for all three
endothelin isopeptides [21, 22]. Receptor binding sites for ET1
have been demonstrated in the renal glomerulus and tubules,
with equal amounts of ETa and ETb in the cortex but predom-
inantly ETb in the deep medulla [23—27]. Infusion of ET1 has
been shown to decrease renal blood flow in rats with a concom-
itant reduction of glomerular filtration rate (GFR) [28—30].
Renal vessels affected by endothelin include the afferent and
efferent arterioles and the arcuate and interlobular arteries [28,
30, 311. Not unexpectedly, the infusion of endothelin also
appears to induce the release of many counter-regulatory hor-
mones, including endothelial-derived relaxing factor (EDRF),
prostaglandin E2 and atrial natriuretic peptide (ANP) [32—34].
The endothelin receptor antagonist, CP170687, is shown in
these experiments to reverse ET1-mediated rat aortic ring
constriction, renal blood flow reduction and elevations in mean
arterial blood pressure. Responses of both renal blood flow and
arterial blood pressure to the antagonist were overcome by high
dose ET1 infusion, suggesting a reversible effect of the inhibitor
as well as possible recruitment of receptors insensitive to the
antagonist. We estimate that the dose of CP170687 utilized in
Time, minutes
Fig. 6. Effects of indomethacin and CP170687 on radiocontrast-
induced vasoconstriction in uninephrectomized salt-depleted rats. Con-
trol rats (•; lothalamate, N = 4) or rats pre-treated with uninephrec-
tomy, salt depletion, and indomethacin (U; iothalamate + US!, N = 7)
were given 6 mI/kg sodium iothalamate while renal blood flow (A) and
mean arterial blood pressure were continuously monitored. These are
compared to US! rats given 6 mg/I00 g CP170687 (U; iothalamate +
USI + CP170687, N = 5) five minutes prior to contrast injection.
Results are expressed as mean SEM. *f < 0.03 vs. US, P < 0.001 vs.
US!; ** < 0.001 vs. US; *** = 0.03 vs. US.
these experiments would probably result in a circulating con-
centration exceeding the IC50 for the ETa receptor (estimated to
be approximately 5 nts; E. McMahon, unpublished observa-
tions), and cannot therefore comment on whether the reversal
of endothelin-mediated renal vasoconstriction is via blockade of
the ETa receptor alone or a combination of both the ETa and
ETb receptor subtypes.
In a recent report by Pollock et al the effect of a different
endothelin receptor antagonist (BQ-123) was examined in ex-
periments with ET1 infusion in the rat [35]. At an endothelin
infusion rate of 25 pmollkg/min (or approximately 9 pmollmin in
a 350 gram rat) they found that this ETa-specific antagonist
reversed only the hypertensive effects of ET1, not the dimin-
ished renal blood flow. These results agree with our own, which
show that at high rates of endothelin infusion (4.2 and 21.7
pmol/min; Fig. 3), CP170687 had a greatly diminished ability to
A
135
125•
115
105
85
75
q)
(U
0
U-
E
E
0
65
*
**
0 10 20 30 40 50 60 70
1222 Cantley et a!: ET antagonist reverses renal vasoconstriction
Fig. 7. Effects of radiocontrast on urinary PGE2 excretion. Urinary
PGE2 (pg/mm, A) and flow rates were determined in rats for 30 minutes
before and three 20-minute periods following either no manipulation (•;
no addition, N = 6), injection of hypertonic saline (0; N = 11),
injection of iothalamate (0; N = 12) or injection of iothalamate +
indomethacin (c:J; N = 3). Results are expressed as mean SEM.
Significance was determined by multivariant ANOVA with repeated
measures comparing all three collection periods. *P < 0.05 vs. no
addition; tP < 0.01 vs. no addition, P < 0.05 vs. hypertonic saline;
< 0.001 vs. no addition.
prevent renal vasoconstriction; whereas at lower doses of
endothelin the effect was fully reversed.
Based on our present knowledge of the ETa and ETb recep-
tors, one possible hypothesis to explain these results is that at
low doses of ET1 the primary renal vasoconstrictive effects are
ETa-mediated and are reversed by CP170687 (and presumably
by BQ-123, although Pollock and coworkers did not investigate
doses in this range). However, at higher doses the intrarenal
ETb receptors are stimulated with a further decrease in renal
blood flow which is not reversed by BQ-123 or low dose
CP170687, and is only partially reversed by high dose CP170687
(probably due to some blockade of the ETb receptor).
The 6.0 mg/100 g body wt dose of CP170687 was subse-
quently used to examine renal blood flow and blood pressure
responses to radiocontrast infusion. In view of previous data
demonstrating an effect of endothelin infusion on renal blood
flow reminiscent of the action of radiocontrast, combined with
the observed doubling of plasma immunoreactive endothelin in
experimental animals following infusion of a number of radio-
contrast agents [7—9], it seemed likely that endothelin might
mediate radiocontrast-induced renal vasoconstriction. Of note,
in the present experiments serum samples for endothelin mea-
surement were not obtained since attempts to do so resulted in
alterations in blood pressure and renal blood flow. However, as
the conditions of radiocontrast infusion were identical to those
previously reported, it is reasonable to assume that a similar
rise in serum endothelin occurred. The results of the present
experiments support a physiologic effect of radiocontrast-in-
duced endothelin release on renal blood flow and mean arterial
blood pressure, and extend this to include prostaglandin secre-
tion as an important moderator of the renovascular effects of
radiocontrast.
Injection of sodium iothalamate resulted in an immediate,
modest decline in renal blood flow, which was not prevented by
blockade of the endothelin receptor and which spontaneously
returned to baseline. Based on the results of Katzberg and his
co-workers, this is probably due to the hypertonicity of the
injected solution rather than a secondary release of norepineph-
rifle, renin, or angiotensin II [4—6]. The data presented here do
not support a role of endothelin in this initial renal vasocon-
strictive response.
Following the injection of sodium iothalamate there is stim-
ulation of urinary PGE2 (as demonstrated in the present exper-
iments) and plasma immunoreactive endothelin-l [7, 9]. The
present experiments suggest that in normal rats, renal vasodi-
latation due to PGE2 (and possibly prostacyclin) rapidly returns
renal blood flow to baseline values. However, when pros-
taglandin synthesis is inhibited, the vasoconstrictive effects of
endothelin predominate and there is prolonged renal hypoper-
fusion. This contrast-induced reduction in renal blood flow was
completely reversed by the endothelin receptor antagonist,
CP170687. These experiments emphasize the importance of
prostaglandin synthesis in modulating the renal vascular re-
sponse to radiocontrast injection. The similarity between re-
sults obtained after indomethacin was given to normal rats and
to uninephrectomized rats depleted of salt strengthens the
earlier observation of Heyman et al that treatment with indo-
methacin was the single most important factor predisposing to
renal injury in their model of radiocontrast nephropathy [1].
The effect of radiocontrast on systemic blood pressure ap-
pears to be primarily mediated by the increase in endothelin. In
normal rats, whether or not prostaglandin synthesis was inhib-
ited, the endothelin receptor antagonist reversed most of the
elevation in mean arterial blood pressure following iothalamate
injection. It is of interest that prostaglandin synthesis inhibition
with indomethacin independently reversed some of the rise in
mean arterial blood pressure, and raises the possibility of a
partial contribution of systemic vasoconstrictive prostaglandins
to the hypertensive response to radiocontrast.
The competitive actions of endothelin and prostaglandins in
regulating renal blood flow are exemplified by these expen-
ments using radiocontrast infusion. It appears that inhibition of
prostaglandin synthesis is critical in prolonging endothelin-
mediated renal vasoconstnction following radiocontrast injec-
tion, although other endogenous vasodilators, like cardiac
peptides [7] or nitric oxide, may also be involved in this
response. The clinical implication of this finding is that suscep-
tibility to radiocontrast-mediated renal injury might be en-
hanced by an exaggerated stimulation of endothelin release or
diminished capacity to synthesize prostaglandins. The former is
likely to be the case in patients with extensive vascular disease
or volume depletion and the latter in elderly patients or those
**
250
200
150
100
50
0
0.5
*
*
I I
0.4
*
**
0.3
0.2
0.1
0
**
**
*
*
*
—3OtoO Oto2O 20to40 40to60
Time of urine collection
Cantley et a!: ET antagonist reverses renal vasoconstriction 1223
with pre-existing renal impairment; both conditions are known
to predispose to radiocontrast nephropathy [36, 37].
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